Study of Advanced Cancer Treatment on Head & Neck Cancer patients and Breast Cancer patients

Not Applicable

• Conditions: Health Condition 1: null- Newly diagnosed, locally advanced Head & Neck Cancer and refractory / relapsed triple negative breast cancer patients

• Registration Number: CTRI/2018/05/013727
• Lead Sponsor: Tata Memorial Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Patients with locally advanced H&N Ca requiring neo-adjuvant therapy, aged 18-75 are eligible for the ACCEPT-H&N trial.

2.Patients from whom at least 100-200 mm3 non-necrotic tumor can be obtained by biopsy or surgery.

3.ECOG Performance Status of 0 â?? 1

Exclusion Criteria

1.Any other concurrent disease or illness, which in the judgment of the investigator

would make the subject inappropriate for entry into the study

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To evaluate the predictive power of CANScriptTM by comparing CANScriptTM outcomes to clinical outcomes at the end of 2/3 cycles of chemotherapy in H&N cancer and TNBC patients.Timepoint: After completion of treatment

Secondary Outcome Measures

Name	Time	Method
1.To evaluate the predictive power of CANScriptTMby comparing CANScriptTM outcome to patientâ??s progression free survival and overall survival when followed for a period of 2 years from study enrollment to disease progression or death (whichever is earlier).Timepoint: After completion of treatment